The FDA has approved Hympavzi to prevent bleeding episodes in hemophilia A and B patients aged 12 and older. This innovative ...

Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved for the blood-clotting disorder ... resumes in northern Gaza Nov. 2 (UPI) -- The third and final phase ...

The government has confirmed it has set aside £11.8bn to compensate victims of the infected blood scandal. More than 30,000 ...

On Friday, the FDA signed off on Hympavzi (marstacimab-hncq), an anti-tissue factor pathway inhibitor ... episodes that accompany the blood-clotting disorder. It is the first U.S.-approved ...

“When HRT is taken transdermally in the form of patch, gel or spray, it is not associated with an increased risk of blood clots, but when it is taken orally there is a very small increase in risk of ...

The global hemophilia treatment market is poised for remarkable growth, with estimates projecting an increase from USD 12.1 billion in 2024 to an impressive USD 18.7 billion by 2034. This substantial ...

Breakthrough polymer-based therapy shows promise in reversing Huntington's disease symptoms by preventing toxic protein ...

Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation ... of 3.2, showing that Hympavzi was superior to on-demand factor replacement.

A BABY was taken away from his parents for six months because of a bruise that was later shown to be not their fault. The ...

A health watchdog has stressed that hormone replacement therapy (HRT) should be the first treatment offered to women with ...

Marstacimab targets the Kunitz 2 domain of TFPI ... The condition is triggered by a clotting factor deficiency—factor VIII in hemophilia A and factor IX in hemophilia B. According to the ...

Pfizer's Hympavzi received FDA approval on October 11, for the treatment of Hemophilia, which becomes the first of its kind to work by targeting a protein in the blood clotting process ... the human ...